Lupus Research Alliance News
The Who, What, Why’s of Lupus

Three lupus experts from Jacobi Medical Center answered these common questions at an educational seminar co-sponsored by the Lupus Research Alliance. Who gets which tests and what do they mean? What can you do to take better care of your skin? Why are you taking each of your medications? Decoding Your Lab Results Asena Bahce-Altuntas, […] READ MORE

Advancing Lupus Care Through Research and Advocacy Conference

The First Collaborative Conference a Great Success The Lupus Research Alliance and Lupus Foundation New England recently co-hosted the Advancing Lupus Care Through Research and Advocacy Conference in Boston. This was the first joint event for the newly merged Lupus Research Alliance, and its success demonstrates the strength of collaboration! Attendees left with hope for […] READ MORE

Make Your Voice Heard on Lupus Drug Development

The national lupus patient advocacy community is excited to announce that people with lupus will have the chance to be part of a history-making project that includes a meeting called Lupus: Patient Voices on September 25 in the Washington, D.C. area. This very important effort is a tremendous opportunity for individuals with lupus to contribute to lupus drug development […] READ MORE

Novel Research Grants Push Discoveries

10 New Grants, 10 New Insights The path to safe and effective treatments and ultimately a cure lies in bold, pioneering research. The Lupus Research Alliance Novel Research Grants, the proven platform for innovation, make discovery and scientific progress possible. “Standing on a 16-year foundation of documented success, the Novel Research Grants bring new insight […] READ MORE

Aurinia Announces Voclosporin Meets 48-Week Remission Endpoints

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH / TSX:AUP) (“Aurinia” or the “Company”), a clinical stage biopharmaceutical company focused on the global immunology market, today announced top-line results from its Phase IIb AURA-LV (AURA) study in lupus nephritis (LN). At 48 weeks, the trial met the complete and partial remission (“CR”/ “PR”) endpoints, demonstrating statistically significantly greater CR […] READ MORE

Together, ManyOne Can make a difference!
Stay informed about events, research developments, and ways you can help. Sign up for updates